Dexamethasone for the Treatment of Depression

A Randomized, Placebo-Controlled, Double-Blind Trial

George W. Arana, Alberto B. Santos, Michele T. Laraia, Stephen McLeod-Bryant, Mark D. Beale, Laura J. Rames, John M. Roberts, James K. Dias, Monica Molloy

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Objective: The authors' goal was to assess dexamethasone for the treatment of depression. Method: Thirty-seven outpatients (11 men and 26 women) meeting DSM-III-R criteria for major depressive disorder were randomly assigned to receive either placebo or 4 mg/day of oral dexamethasone for 4 days. Baseline Hamilton depression scale scores were compared with scores obtained 14 days after the first dose of study medication. Data were analyzed by using two-sample t tests, chi-square methods, and Fisher's exact test. Results: Seven (37%) of the 19 patients given dexamethasone but only one (6%) of the 18 patients given placebo responded positively. No adverse events or side effects were reported, and all patients who entered the study completed it. Conclusions: A brief course of oral dexamethasone (4 days) was significantly more effective than placebo within 14 days for the treatment of depression in a randomized, double-blind study of depressed outpatients.

Original languageEnglish (US)
Pages (from-to)265-267
Number of pages3
JournalAmerican Journal of Psychiatry
Volume152
Issue number2
StatePublished - Feb 1995
Externally publishedYes

Fingerprint

Dexamethasone
Placebos
Depression
Outpatients
Major Depressive Disorder
Chi-Square Distribution
Therapeutics
Double-Blind Method
Diagnostic and Statistical Manual of Mental Disorders

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Arana, G. W., Santos, A. B., Laraia, M. T., McLeod-Bryant, S., Beale, M. D., Rames, L. J., ... Molloy, M. (1995). Dexamethasone for the Treatment of Depression: A Randomized, Placebo-Controlled, Double-Blind Trial. American Journal of Psychiatry, 152(2), 265-267.

Dexamethasone for the Treatment of Depression : A Randomized, Placebo-Controlled, Double-Blind Trial. / Arana, George W.; Santos, Alberto B.; Laraia, Michele T.; McLeod-Bryant, Stephen; Beale, Mark D.; Rames, Laura J.; Roberts, John M.; Dias, James K.; Molloy, Monica.

In: American Journal of Psychiatry, Vol. 152, No. 2, 02.1995, p. 265-267.

Research output: Contribution to journalArticle

Arana, GW, Santos, AB, Laraia, MT, McLeod-Bryant, S, Beale, MD, Rames, LJ, Roberts, JM, Dias, JK & Molloy, M 1995, 'Dexamethasone for the Treatment of Depression: A Randomized, Placebo-Controlled, Double-Blind Trial', American Journal of Psychiatry, vol. 152, no. 2, pp. 265-267.
Arana, George W. ; Santos, Alberto B. ; Laraia, Michele T. ; McLeod-Bryant, Stephen ; Beale, Mark D. ; Rames, Laura J. ; Roberts, John M. ; Dias, James K. ; Molloy, Monica. / Dexamethasone for the Treatment of Depression : A Randomized, Placebo-Controlled, Double-Blind Trial. In: American Journal of Psychiatry. 1995 ; Vol. 152, No. 2. pp. 265-267.
@article{688d04814b874c088e96c94c9443655d,
title = "Dexamethasone for the Treatment of Depression: A Randomized, Placebo-Controlled, Double-Blind Trial",
abstract = "Objective: The authors' goal was to assess dexamethasone for the treatment of depression. Method: Thirty-seven outpatients (11 men and 26 women) meeting DSM-III-R criteria for major depressive disorder were randomly assigned to receive either placebo or 4 mg/day of oral dexamethasone for 4 days. Baseline Hamilton depression scale scores were compared with scores obtained 14 days after the first dose of study medication. Data were analyzed by using two-sample t tests, chi-square methods, and Fisher's exact test. Results: Seven (37{\%}) of the 19 patients given dexamethasone but only one (6{\%}) of the 18 patients given placebo responded positively. No adverse events or side effects were reported, and all patients who entered the study completed it. Conclusions: A brief course of oral dexamethasone (4 days) was significantly more effective than placebo within 14 days for the treatment of depression in a randomized, double-blind study of depressed outpatients.",
author = "Arana, {George W.} and Santos, {Alberto B.} and Laraia, {Michele T.} and Stephen McLeod-Bryant and Beale, {Mark D.} and Rames, {Laura J.} and Roberts, {John M.} and Dias, {James K.} and Monica Molloy",
year = "1995",
month = "2",
language = "English (US)",
volume = "152",
pages = "265--267",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "2",

}

TY - JOUR

T1 - Dexamethasone for the Treatment of Depression

T2 - A Randomized, Placebo-Controlled, Double-Blind Trial

AU - Arana, George W.

AU - Santos, Alberto B.

AU - Laraia, Michele T.

AU - McLeod-Bryant, Stephen

AU - Beale, Mark D.

AU - Rames, Laura J.

AU - Roberts, John M.

AU - Dias, James K.

AU - Molloy, Monica

PY - 1995/2

Y1 - 1995/2

N2 - Objective: The authors' goal was to assess dexamethasone for the treatment of depression. Method: Thirty-seven outpatients (11 men and 26 women) meeting DSM-III-R criteria for major depressive disorder were randomly assigned to receive either placebo or 4 mg/day of oral dexamethasone for 4 days. Baseline Hamilton depression scale scores were compared with scores obtained 14 days after the first dose of study medication. Data were analyzed by using two-sample t tests, chi-square methods, and Fisher's exact test. Results: Seven (37%) of the 19 patients given dexamethasone but only one (6%) of the 18 patients given placebo responded positively. No adverse events or side effects were reported, and all patients who entered the study completed it. Conclusions: A brief course of oral dexamethasone (4 days) was significantly more effective than placebo within 14 days for the treatment of depression in a randomized, double-blind study of depressed outpatients.

AB - Objective: The authors' goal was to assess dexamethasone for the treatment of depression. Method: Thirty-seven outpatients (11 men and 26 women) meeting DSM-III-R criteria for major depressive disorder were randomly assigned to receive either placebo or 4 mg/day of oral dexamethasone for 4 days. Baseline Hamilton depression scale scores were compared with scores obtained 14 days after the first dose of study medication. Data were analyzed by using two-sample t tests, chi-square methods, and Fisher's exact test. Results: Seven (37%) of the 19 patients given dexamethasone but only one (6%) of the 18 patients given placebo responded positively. No adverse events or side effects were reported, and all patients who entered the study completed it. Conclusions: A brief course of oral dexamethasone (4 days) was significantly more effective than placebo within 14 days for the treatment of depression in a randomized, double-blind study of depressed outpatients.

UR - http://www.scopus.com/inward/record.url?scp=0028888749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028888749&partnerID=8YFLogxK

M3 - Article

VL - 152

SP - 265

EP - 267

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 2

ER -